RMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ResMed Inc (RMD) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While the company's financial performance is solid and analysts maintain positive ratings, the lack of immediate positive trading signals, neutral technical indicators, and bearish short-term stock trend projections suggest holding off on purchasing right now.
The MACD is positive at 1.324 but contracting, indicating weakening momentum. RSI is neutral at 36.142, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level (227.208), with support at 221.136 and resistance at 233.28. Overall, technical indicators suggest a neutral to slightly bearish sentiment.
The company reported strong Q2 financials with double-digit revenue and earnings growth, improved gross margins, and positive analyst ratings. ResMed remains a global leader in the sleep apnea market, which provides a long-term growth narrative.
The stock has a bearish short-term trend with a 50% chance of declining by -3.01% in the next day, -6.67% in the next week, and -7.96% in the next month. Options data also reflects bearish sentiment, and there are no recent news or significant trading trends from insiders or hedge funds to act as catalysts.
In Q2 2026, ResMed's revenue increased by 10.98% YoY to $1.42 billion, net income rose by 13.92% YoY to $392.6 million, EPS grew by 14.53% YoY to $2.68, and gross margin improved by 5.52% YoY to 60.93%. The company demonstrated strong financial growth and operational efficiency.
Analysts maintain a positive outlook on ResMed. JPMorgan initiated coverage with an Overweight rating and a price target of A$37.60. Evercore ISI, Citi, and other firms have adjusted price targets but maintain Buy or Outperform ratings. However, some firms like Piper Sandler and Stifel remain Neutral, citing modest growth and minor concerns.
